IRON

75.1401.27%
BM

Brian MacDonald

Founder & Chair of Scientific Advisory Board

Dr. Brian MacDonald, MB, ChB, Ph.D., was the Chief Innovation Officer of Disc Medicine Opco Inc (formerly known as Disc Medicine, Inc.). since September 2021 until December 2023 and serves as its Chair of Scientific Advisory Board since December 2023. He is Founder of Disc Medicine Opco Inc (formerly known as Disc Medicine, Inc.). and served as its Interim Chief Executive Officer (October 2017 to February 2020) and was its Senior Advisor and Director (February 2020 to September 2021). He was the Chief Executive Officer of Merganser Biotech, Inc., from September 2011 through July 2016. He served as Senior Clinical Advisor of Azelon Pharmaceuticals, Inc. Dr. MacDonald served as Chief Executive Officer of Zelos Therapeutics Inc. since October 18, 2005 until September 2011. He served as Vice President of Development of TetraLogic Pharmaceuticals, Inc. (formerly Gentara Corporation). He was also previously Head of Regulatory Affairs at Tetralogic from 2004 to 2005. Dr. MacDonald has a strong track record of achievement in the pharmaceutical industry, with a particular emphasis on the development of novel therapeutics for the treatment of osteoporosis. Dr. MacDonald joined SmithKline Beecham Clinical R&D in 1995 and was responsible for osteoporosis and rheumatology, a role that he extended following the merger to form GlaxoSmithKline to include a range of therapeutic areas including dermatology and analgesia. In 2002, he joined 3-Dimensional Pharmaceuticals as Vice President of Development until its acquisition by J&J in 2003. He has consulted on R&D strategy for numerous early stage biotech companies as Head of Clinical and Regulatory Affairs for Gentara Corporation. From 1995 to 2002, he served at GlaxoSmithKiine Pharmaceuticals Clinical Research and Development Group Director for Emerging Therapeutic Areas (2000 to 2002). He serves as a Member of Advisory Board of Azelon Pharmaceuticals, Inc. Dr. MacDonald serves as a Director of Zelos Therapeutics Inc. He is a member of the Royal College of Physicians. Dr. MacDonald has a PhD and MB, ChB from the Sheffield Medical School, University of Sheffield in the UK. He undertook specialty clinical training in metabolic bone disease and rheumatology.

Positions